Your browser is no longer supported. Please, upgrade your browser.
VTVT [NASD]
vTv Therapeutics Inc.
Index- P/E- EPS (ttm)-0.08 Insider Own54.82% Shs Outstand61.07M Perf Week-11.80%
Market Cap73.92M Forward P/E- EPS next Y-0.33 Insider Trans-0.16% Shs Float30.20M Perf Month-28.00%
Income-4.80M PEG- EPS next Q-0.07 Inst Own5.10% Short Float5.64% Perf Quarter-48.28%
Sales10.40M P/S7.11 EPS this Y69.50% Inst Trans0.23% Short Ratio3.68 Perf Half Y-63.82%
Book/sh-0.35 P/B- EPS next Y-88.20% ROA-22.70% Target Price6.75 Perf Year-64.00%
Cash/sh0.19 P/C3.77 EPS next 5Y- ROE9.40% 52W Range0.70 - 3.79 Perf YTD-26.19%
Dividend- P/FCF- EPS past 5Y44.20% ROI14.80% 52W High-80.62% Beta-1.58
Dividend %- Quick Ratio4.00 Sales past 5Y65.30% Gross Margin- 52W Low4.42% ATR0.07
Employees25 Current Ratio4.00 Sales Q/Q42757.10% Oper. Margin-83.90% RSI (14)26.98 Volatility13.02% 8.25%
OptionableNo Debt/Eq- EPS Q/Q44.00% Profit Margin-46.30% Rel Volume0.66 Prev Close0.77
ShortableYes LT Debt/Eq- EarningsNov 09 BMO Payout- Avg Volume463.83K Price0.73
Recom2.00 SMA20-17.94% SMA50-33.46% SMA200-59.28% Volume309,004 Change-4.44%
May-30-19Initiated H.C. Wainwright Buy
Apr-10-18Downgrade Stifel Buy → Hold $12 → $1
Mar-08-18Initiated ROTH Capital Buy $17
Feb-08-18Initiated Northland Capital Outperform $28
Sep-26-16Initiated H.C. Wainwright Buy $13
Sep-04-15Initiated Canaccord Genuity Buy $15
Aug-24-15Initiated Stifel Buy $17
Aug-24-15Initiated Piper Jaffray Overweight $24
Jan-13-22 08:30AM  
Jan-12-22 05:38PM  
Dec-06-21 06:43PM  
05:19PM  
Dec-03-21 10:00AM  
Nov-22-21 06:06AM  
Nov-09-21 09:45AM  
08:30AM  
Oct-28-21 03:06PM  
01:38PM  
Oct-20-21 09:00AM  
Oct-12-21 07:30AM  
Sep-23-21 04:30PM  
Sep-13-21 03:40PM  
Aug-17-21 10:00AM  
Aug-04-21 07:15PM  
04:30PM  
Jul-27-21 07:50AM  
Jun-29-21 07:30AM  
Jun-22-21 09:48PM  
10:11AM  
08:28AM  
07:30AM  
May-25-21 07:57AM  
May-05-21 08:45PM  
04:10PM  
Apr-14-21 09:03AM  
Apr-13-21 07:30AM  
Apr-12-21 04:30PM  
Mar-23-21 07:30AM  
Mar-18-21 04:05PM  
Mar-08-21 04:05PM  
Mar-03-21 04:21AM  
Feb-24-21 04:30PM  
Feb-23-21 10:30AM  
Feb-17-21 04:05PM  
Jan-06-21 04:30PM  
Dec-15-20 06:15PM  
09:05AM  
07:30AM  
Dec-02-20 12:50PM  
Nov-28-20 08:51PM  
Nov-24-20 04:30PM  
Nov-05-20 04:30PM  
Nov-04-20 07:30AM  
Oct-29-20 02:08PM  
07:30AM  
Sep-23-20 07:30AM  
Sep-16-20 07:30AM  
Sep-15-20 07:30AM  
Aug-03-20 04:30PM  
Jul-27-20 07:30AM  
Jun-13-20 11:00AM  
Jun-04-20 07:08PM  
May-28-20 11:15AM  
May-27-20 07:30AM  
May-22-20 04:30PM  
May-12-20 10:38AM  
May-07-20 04:30PM  
Mar-12-20 11:30AM  
Mar-02-20 08:10AM  
Feb-25-20 05:00AM  
Feb-24-20 11:24AM  
Feb-20-20 06:58PM  
Feb-10-20 07:00AM  
Feb-07-20 04:05PM  
Jan-31-20 11:52AM  
Jan-10-20 12:32PM  
Jan-03-20 06:00AM  
Dec-19-19 05:45AM  
Dec-02-19 07:30AM  
06:45AM  
Nov-15-19 03:04PM  
Nov-05-19 07:30AM  
Oct-30-19 06:55PM  
05:30PM  
Oct-25-19 02:03PM  
Oct-03-19 07:30AM  
Sep-20-19 03:28PM  
10:02AM  
Sep-18-19 07:30AM  
Sep-17-19 04:35PM  
Sep-13-19 01:32PM  
Sep-11-19 07:30AM  
Sep-06-19 04:06PM  
Sep-04-19 07:30AM  
Aug-09-19 04:09PM  
Aug-06-19 04:05PM  
Jul-31-19 04:30PM  
Jul-15-19 04:59PM  
Jun-28-19 01:03PM  
Jun-27-19 04:30PM  
Jun-06-19 08:00AM  
May-29-19 12:00PM  
May-17-19 05:47PM  
May-01-19 06:58PM  
04:30PM  
Apr-04-19 10:49AM  
Apr-03-19 07:57AM  
Apr-02-19 07:30AM  
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PDE4 inhibitor; HPP737, a PPAR-delta agonist; and an Nrf2 activator through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERELMAN RONALD O10% OwnerDec 20Sale1.1587,000100,05036,519,212Dec 21 04:51 PM
Nelson Rich S.DirectorFeb 26Buy2.8610,00028,60010,000Mar 02 04:03 PM
Nelson Rich S.DirectorFeb 26Buy2.8650,000143,00050,000Mar 02 04:03 PM
KOZLOV HERSHDirectorFeb 26Buy2.7410,00027,40025,000Mar 02 04:03 PM